2023 World Conference on Lung Cancer (Posters)-EP08.02. Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience

EP08.02. Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the outcomes of patients with stage IIb-III non-small cell lung cancer (NSCLC) who were not eligible for standard chemoradiotherapy and instead received definitive hypofractionated radiation therapy (HFRT) followed by systemic therapy and/or immunotherapy. The study included 41 eligible patients with a median age of 73, and the majority had advanced stage tumors (T3-T4) and nodal involvement (N2-N3). The patients received a median dose of 60 Gy in 15 fractions using either linear accelerator or proton therapy. Some patients also received sequential chemotherapy or immunotherapy after HFRT. <br /><br />The median follow-up length was 12.2 months, and the median overall survival was 9 months while the median progression-free survival was 6 months for the entire cohort. The addition of immunotherapy after HFRT did not significantly improve progression-free survival or overall survival. Of the patients, 17 experienced disease recurrence, with a median time to recurrence of 6 months. Most recurrences were locoregional, with only 2 patients having distant sites of progression. <br /><br />In terms of side effects, 32% of patients had no reported treatment-related toxicities, while 54% experienced grade 1 side effects such as fatigue, cough, and dyspnea. Only 19% of patients experienced grade 2 side effects, and there were no grade 3 or higher adverse effects reported. <br /><br />Overall, this institutional experience suggests that definitive HFRT can be safely delivered with a favorable side effect profile for patients with unresectable NSCLC who are not eligible for standard chemoradiotherapy. However, the addition of consolidative immunotherapy after HFRT did not significantly improve outcomes in this patient population.

Asset Subtitle

Benjamin Hopkins

Meta Tag

Speaker Benjamin Hopkins

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

stage IIb-III non-small cell lung cancer

NSCLC

chemoradiotherapy

hypofractionated radiation therapy

systemic therapy

immunotherapy

linear accelerator

proton therapy

overall survival

progression-free survival